Stage IVB Rectal Cancer: Clinical Trials

11 trials for Stage IVB Rectal Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 terminated, 3 withdrawn. 11 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 4, Terminated 4, Withdrawn 3
Phase 13Completed 1, Terminated 1, Withdrawn 1

Follow Stage IVB Rectal Cancer: new trials by email Literature Review of Stage IVB Rectal Cancer trials Research Report on Stage IVB Rectal Cancer

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Capecitabine, Laboratory Biomarker Analysis, Nintedanib - Colon Adenocarcinoma, Rectal Adenocarcinoma
Phase 1 / Phase 2CompletedRoswell Park Cancer Institute422015-05-082021-07-08
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Phase 2WithdrawnUniversity of Southern California2015-03-012015-05-06
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)182013-03-012019-09-20
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy - Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
Phase 2TerminatedUniversity of Washington272013-03-012018-01-16
Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer
Phase 2TerminatedVanderbilt-Ingram Cancer Center302011-06-012014-08-26
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
oxaliplatin, leucovorin calcium, fluorouracil - Liver Metastases, Recurrent Colon Cancer
Phase 2TerminatedCity of Hope Medical Center12011-03-012016-07-19
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase 2WithdrawnNational Cancer Institute (NCI)2010-12-012017-04-04
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer
Phase 2CompletedNational Cancer Institute (NCI)642005-01-012015-03-02
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
cetuximab, bevacizumab, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer
Phase 2CompletedNational Cancer Institute (NCI)702003-12-012015-04-15
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
fluorouracil, sodium phenylbutyrate, indomethacin - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)461997-05-012013-02-01
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 1 / Phase 2WithdrawnRoswell Park Cancer Institute2016-05-20

Narrower conditions

Colonic Neoplasms (11)  ·  Rectal Neoplasms (11)  ·  Pancreatic Neoplasms (1)

Broader conditions

Colonic Diseases (11)  ·  Colorectal Neoplasms (11)  ·  Digestive System Diseases (11)  ·  Digestive System Neoplasms (11)  ·  Gastrointestinal Diseases (11)  ·  Gastrointestinal Neoplasms (11)  ·  Intestinal Diseases (11)  ·  Intestinal Neoplasms (11)  ·  Neoplasms (11)  ·  Neoplasms by Site (11)  ·  Rectal Diseases (11)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Pancreatic Diseases (1)

Interventions

Fluorouracil (5)  ·  Bevacizumab (3)  ·  Irinotecan (3)  ·  Leucovorin (3)  ·  Oxaliplatin (3)  ·  Capecitabine (2)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  4-phenylbutyric acid (1)  ·  Celecoxib (1)  ·  Cetuximab (1)  ·  Folfox protocol (1)  ·  Indomethacin (1)  ·  Interferon-gamma (1)  ·  MK 2206 (1)  ·  Radiation (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Roswell Park Cancer Institute (2)  ·  City of Hope Medical Center (1)  ·  University of Southern California (1)  ·  University of Washington (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (11)

Top investigators

Afsaneh Barzi (1)  ·  Christos Fountzilas (1)  ·  Edmund Kopetz (1)  ·  Jeffrey Wong (1)  ·  Jordan Berlin, MD (1)  ·  Leonard Saltz (1)  ·  Max Sung (1)  ·  Neil Segal (1)  ·  Stacey Cohen (1)  ·  Syma Iqbal, MD (1)  ·  Wen Wee Ma (1)

Results publications

PMID 38697618

NIH funding

P30CA016056 (2), N01CM00039 (1), N01CM17101 (1), N01CM17102 (1), N01CM17103 (1), N01CM17105 (1), N01CM62206 (1), P01CA043904 (1), P30CA014089 (1), P30CA015704 (1), P30CA016672 (1), U01CA069856 (1)